Wednesday, April 24, 2024
HomeFunding CA-based Carlsmed Secures $52.5Million in Series C Round Funding

[Funding alert] CA-based Carlsmed Secures $52.5Million in Series C Round Funding

Carlsmed, an AI-enabled personalized surgery Medtech company secures $52.5million in series C round funding. This round was co-led by B Capital and U.S. Venture Partners.

Carlsmed, an AI-enabled personalized surgery Medtech company secures $52.5million in series C round funding. This round was co-led by B Capital and U.S. Venture Partners.

These proceeds will be used to accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo® for cervical fusions, which will launch in 2025.

Read also – NYC-based BigID Secures $60Million in Growth Funding

Mike Cordonnier, CEO of Carlsmed said, “We started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevo® patient specific implants are achieving this goal, Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients.”

Dr. Robert Mittendorff, General Partner and Head of Healthcare at B Capital, said, “It is transforming spine surgery through the application of its AI-enabled technology and has proven to be a category creator in a market overdue for meaningful innovation. Personalized surgery will be the standard of care in spine, and we look forward to supporting this transformation led by Carlsmed.”

It has received Breakthrough Device designation by the FDA for aprevo® lumbar and cervical patient-specific interbody fusion devices. It’s implantable devices and software platforms are FDA cleared for lumbar spine fusion, including anterior, lateral, and transforaminal approaches.

About Carlsmed

Carlsmed creates customized aprevo® spine fusion devices and the best surgical strategies for each patient using patient data and exclusive digital technology. Commercially available in the United States, the Carlsmed® aprevo® devices have received FDA clearance and FDA Breakthrough Designation, an unprecedented honor for any implanted device in the industry.

Read also – CA-based Superlinked Secures $9.5Million in Seed Funding

It’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery. The aprevo® personalized surgery platform is designed to advance the standard of care for spine surgery one patient at a time.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular